rifabutin (mycobutin) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. It is FDA approved for the prophylaxis of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. Multiple dosing of rifabutin has been associated with induction of hepatic metabolic enzymes of the CYP3A subfamily. Rifabutin’s predominant metabolite (25-desacetyl rifabutin: LM565), may also contribute to this effect. Similarly, concomitant medications that competitively inhibit the CYP3A activity may increase plasma concentrations of rifabutin. Common adverse reactions include discoloration of skin, rash, diarrhea, disorder of taste, indigestion, loss of appetite, nausea, vomiting, increased liver aminotransferase level (mild), ocular discoloration, uveitis, abnormal color of body fluid.   NCATS

Chemistry

  • SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(=O)C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)=C5NC6(CCN(CC(C)C)CC6)N=C5C4=C3C2=O
  • InChIKey: ATEBXHFBFRCZMA-VXTBVIBXSA-N
  • Mol. Mass: 847.0047
  • ALogP: 4.62
  • ChEMBL Molecule:
    rifabutin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$3.3974

United States

$5.7609 - $12.3278
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( amoxicillin, rifabutin (mycobutin), omeprazole (prilosec) - other name: omeprazole magnesium, amoxicillin, rifabutin )

Alternative names

1,4-dihydro-1-deoxy-1',4-didehydro-5'-(2-methylpropyl)-1-oxorifamycin xiv | 4-deoxo-3,4-(2-spiro(n-isobutyl-4-piperidyl)-2,5-dihydro-1h-imidazo)-rifamycin s | 4-n-isobutylspiropiperidylrifamycin s | ansamicin | ansamycin | lm-427 | mycobutin | mycobutin (tn) | rifabutin | rifabutina | rifabutine | rifabutinum

Organizations (87)

Research & Development (84)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (29)

Approved Indications (2)


 

HIV Infections

Mycobacterium avium-intracellulare Infection (approved 1992)

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Analgesics, Opioid (Phase 1)

Bacterial Infections (Phase 3)

Chlamydia (Phase 2)

Coronary Disease (Phase 2)

Crohn Disease (Phase 4)

Drug Interactions (Phase 4)

Drug Resistance, Bacterial (Phase 3)

Drugs, Investigational (Phase 1)

Dyspepsia (Phase 3)

Gastritis (Phase 3)

Healthy Volunteers (Phase 1)

Helicobacter Infections (Phase 3)

Helicobacter pylori (Phase 4)

HIV (Phase 2)

HIV Infections ()

Infections (Phase 3)

Kidney Failure, Chronic (Phase 1)

Lung Diseases (Phase 3)

Male (Phase 1)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Mycobacterium (Phase 1)

Mycobacterium avium Complex (Phase 4)

Mycobacterium avium-intracellulare Infection (Phase 4)

Mycoses (Phase 3)

Respiratory Tract Infections (Phase 4)

Sprains and Strains (Phase 3)

Staphylococcus aureus (Phase 2)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 75
  • # of Trial Organizations: 84

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue